Novartis announce plans to return rights of Oncology antibody to Aveo

05 July 2018
Pharma

In a deal valued at at least $326 million just announced, Novartis will return the Oncology antibody to Aveo. The AV-380 antibody targets GDF15. In an SEC filing, Aveo said it has received a 'notice of termination' of the license agreement with Novartis. This agreement gave Novartis exclusive worldwide right to develop and commercialise AV-380 and related Aveo antibodies that inhibit GDF15.

Though Novartis regard the programme 'an important asset', they also maintain that development delays, and ultimately an internal decision not to continue further development as the key reason to hand back the license. Novartis also said that changes in management and strategic priorities within the firm were central to their decision.

This news is not totally unexpected, as Aveo were involved with filing a dispute notification regarding Novartis’ compliance with its 'diligence obligations' as part of the development of AV-380. Aveo had stated that 'if the parties are unable to resolve the dispute at the management level, an arbitration could be commenced'.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever